Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dostarlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dostarlimab | TSR-042 | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67 | Dostarlimab (TSR-042) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (Eur J Cancer 2016 Dec; 69 (Suppl 1):S102, Abstract # 310, PMID: 31847708, PMID: 32213091). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | Dostarlimab | Phase I | Actionable | In a Phase I trial, Dostarlimab (TSR-042) demonstrated safety and preliminary efficacy, resulted in partial response in 9.5% (2/21) and stable disease in 23.8% (5.21) of patients with advanced solid tumors (Annals of Oncology (2017) 28 (suppl_5): v403-v427. Abstract # 1185P; NCT02715284). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04139902 | Phase II | Dostarlimab + TSR-022 Dostarlimab | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Recruiting | USA | 0 |
NCT02715284 | Phase I | Dostarlimab | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) | Recruiting | USA | CAN | 7 |
NCT03955978 | Phase I | Dostarlimab | TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer | Recruiting | USA | 0 |
NCT04774419 | Phase II | Dostarlimab | Radiation and TSR-042 in People With Endometrial Cancer After They Receive Surgery | Recruiting | USA | 0 |